Related Experiment Video

Updated: Sep 27, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction

Pieter Martens1

  • 1Kauffman Center for Heart Failure Treatment and Recovery, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic, Cleveland, OH, US.

Cardiac Failure Review
|April 11, 2022
PubMed

Insights

Iron deficiency negatively impacts heart failure with reduced ejection fraction. Ferric carboxymaltose treatment can improve cardiac function and structure in these patients.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Iron deficiency significantly impairs functional status, quality of life, and exercise capacity in heart failure with reduced ejection fraction (HFrEF).
  • Iron deficiency negatively affects mitochondrial function and cardiac energetics in HFrEF, leading to reduced systolic function and cardiac performance.

Purpose of the Study:

  • To discuss the impact of iron deficiency on cardiac function and structure in HFrEF.
  • To explore how iron deficiency in HFrEF can be alleviated.

Main Methods:

  • Review of mechanistic studies on iron deficiency in HFrEF.
  • Analysis of data from the IRON-CRT trials.

Main Results:

  • Iron deficiency detrimentally affects functional status, quality of life, cardiac function, structure, and exercise capacity in HFrEF.
  • The IRON-CRT trials demonstrated that ferric carboxymaltose improves cardiac structure and performance.

Conclusions:

  • Iron deficiency has a profound negative impact on patients with HFrEF.
  • Treatment with ferric carboxymaltose shows promise in alleviating the adverse effects of iron deficiency on cardiac function and structure in HFrEF.

Keywords:
Iron deficiencycardiac physiologyferric carboxymaltoseheart failurepharmacologyremodelling

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.7K
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes08:19

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

Published on: June 22, 2020

6.6K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
81
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
95
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
57
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
57